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Background: Mydriasert is an insoluble ophthalmic insert indicated for mydriasis prior to cataract surgery, which
gradually releases the active ingredients: tropicamide (0.25 mg) and phenylephrine (5.38 mg). This study aimed to
evaluate the cost of Mydriasert compared with conventional mydriatic eye drops to induce pupil dilation prior to
cataract surgery using a budget impact model.
Methods: A cohort-based, decision tree, budget impact model was developed to estimate the drug, consumable
and staff costs for achieving mydriasis with Mydriasert compared to mydriatic eye drops (tropicamide [1 %] plus
phenylephrine [10 %]). Insights from structured interviews with clinicians (n = 5) experienced in using both
Mydriasert and mydriatic eye drops and results from the current clinical study of patients undergoing cataract
surgery (n = 144) at a Greater London district general hospital were used to obtain key input parameters for
the model, and to validate the model approach.
Results: The base case analysis in a cohort of 1763 patients undergoing cataract surgery showed that when
Mydriasert substituted mydriatic eye drops, annual total costs decreased by 18 % and annual total nurse time
decreased from 235.1 hours to 44.1 hours over one year (2012–2013).
Conclusions: This study demonstrated that despite its higher unit cost than mydriatic eye drops, Mydriasert resulted
in overall savings in health-care costs, mainly associated with reduced nursing time. The economic model developed
could assist National Health Service managers and local payers to estimate the budget impact of the introduction of
Mydriasert into different clinical settings.
Keywords: Mydriasert, Mydriasis, Mydriatics, Mydriatic eye drops, Cataract surgery, Economic modelBackground
Efficient and stable mydriasis is necessary during many
diagnostic and surgical procedures in ophthalmology
[1, 2]. Mydriasert® (Laboratoires Théa) is an insoluble
ophthalmic insert indicated for pre-surgical mydriasis,
which gradually releases the active ingredients: tropicamide
(0.25 mg) and phenylephrine (5.38 mg) [3]. Published
studies have demonstrated that Mydriasert is effective in
achieving stable mydriasis compared to conventional
topical mydriatic eye drop regimes [1–8] with a good
safety profile [6] and a faster recovery of near vision after
dilation of the pupil [1, 6].* Correspondence: Sukhvinder.Johal@parexel.com
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© 2015 Shah et al.The unit cost of Mydriasert is several times greater than
that of eye drops [9]; however, there may be considerable
cost-savings in nursing time for multiple instillations of
pre-operative drops compared to a one-off insertion of a
Mydriasert pellet.
This study aimed to evaluate the cost of Mydriasert
compared to conventional mydriatic eye drops (tropicamide
[1 %] plus phenylephrine [10 %]) to induce pupil dilation
prior to cataract surgery using a budget impact model. A
prospective clinical evaluation of the introduction of
Mydriasert for pre-operative pupillary dilation in a Greater
London district general hospital ophthalmology department
provided input parameters for the economic model. The
economic model was designed to assist National Health
Service (NHS) managers and local payers in considering
the cost implications of introducing Mydriasert into
different clinical settings.
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Budget impact model structure
A budget impact model was developed to estimate
the drug, consumable and staff costs for achieving
mydriasis with Mydriasert compared to mydriatic eye
drops (tropicamide [1 %] plus phenylephrine [10 %]).
The model was designed to give maximum flexibility to
the user by allowing a choice of analysis perspectives
(national, health commissioning board, local clinical
commissioning groups or clinic etc.) and changes to all
input parameters such as the proportion of patients
treated with Mydriasert or mydriatic eye drops, drug
prices and resource use/staff time.
The budget impact model was cohort-based, utilised a
decision tree structure (Fig. 1) and followed patients
from cataract surgery preparation to the post-surgery
recovery period. It calculated costs for an estimated cohort
of patients over a one year time horizon. The analysis
aimed to capture all costs and outcomes relevant to the
NHS to identify any differences in annual costs between
the use of Mydriasert and mydriatic eye drops [10].
Base case analysis
In the base case analysis of a single London hospital popu-
lation of 1763 patients undergoing cataract surgery, a direct
comparison of costs of the two treatment options (treating
all patients with Mydriasert compared to treating all
patients with mydriatic eye drops [1 % tropicamide and
10 % phenylephrine]) was conducted. The main economic
outcomes evaluated were total costs and nurse time saved.
Budget impact model inputs
Structured interviews with 5 clinicians experienced in using
both Mydriasert and mydriatic eye drops based in differentFig. 1 Budget impact model structure. The model follows a cohort of patie
mydriasis using Mydriasert and eye drops (tropicamide [1 %] and phenylep
costs and outcomes relevant to the NHS and to capture any significant difcentres in the UK were conducted in February 2013.
Insights from these interviews and results from a
current clinical study [11] of patients (n = 144) undergoing
cataract surgery (from September 2012 to April 2013)
were used to obtain key input parameters for the model,
and to validate the model approach. In addition, drug
prices used in the model were obtained from the British
National Formulary (2013) [9], and surgical consultant
and nurse costs were obtained from the Personal Social
Services Research Unit (2012) [12].
Input parameters included in the base case analysis
are summarised in Table 1. In the clinical study, a
proforma for nursing staff (collected over 4 weeks),
recorded the amount of time spent inserting the pellet
and included a patient satisfaction score on a scale of
1 to 10, with 1 indicating highly dissatisfied and 10
indicating highly satisfied. Surgical proformas recording
pupil size according to the classification shown in Fig. 2a,
time since Mydriasert insertion (for the first 50 cases) and
any adverse events were registered by a single surgeon
over 6 months [11]. Data was collected on all consecutive
cases operated on over the 6 month period. Cases were
deemed suitable for a senior specialty registrar and
included eyes noted to dilate poorly in clinic and patients
on agents known to cause intra-operative floppy iris
syndrome such as tamsulosin and doxazocin. The study
was carried out with the approval of the Research and
Development committee at Hillingdon Hospital NHS
Foundation Trust, London, UK.
Budget impact model assumptions
The underlying assumption for the budget impact model
described was that Mydriasert and mydriatic eye drops
had equivalent health and surgical outcomes for patientsnts, and calculates the drug, consumable and staff costs for achieving
hrine [10 %]). The structure of the analysis aimed to incorporate all
ferences in costs between treatments
Table 1 Input parameters for the base case cost analysis of
Mydriasert compared to eye drops for mydriasis during cataract




Mydriatic drops (cost per vial)a
Tropicamide (1 %) £0.47
Phenylephrine (10 %) £0.49
Resource utilisation and costs
Surgical consultant cost per minute £2.45
Nurse cost per minute £0.70
Mydriasert: number of instillations 1
Eye drops: number of instillations 4
Time to instil Mydriasert 1.5 minutes
Time to instil eye drops 2 minutes
Percentage of Mydriasert inserts that extrude 2.6 %
The majority of input parameters were obtained from the current clinical study
or insights from clinician interviews with the exception of drug prices from the
British National Formulary (2013)8 and surgical consultant and nurse costs
obtained from the Personal Social Services Research Unit (2012) 10. a For eye
drops it was assumed one vial was used per patient
Fig. 2 Pupil size score a and scatter plot comparing pupil size score
against time since Mydriasert insertion b. a Pupil size score was
recorded at the start of surgery after Mydriasert insertion to evaluate
the efficacy and record Mydriasert extrusions and b time since
Mydriasert insertion was also recorded for the first 50 cases. Mins,
minutes; mm, millimetre.
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related to cataract surgery were not included in the model.
It was also assumed that the time to remove the Mydriasert
was negligible and added no extra time to surgery.
Parameters were varied in univariate sensitivity analyses
to assess model robustness.
Scenario analysis
In the event that pupil dilation was not sufficient to perform
cataract surgery, iris hooks were sometimes used to achieve
a larger pupil. The additional costs of iris hook use were
considered in a scenario analysis. Surgical theatre order
books were reviewed to determine the number of iris hooks
ordered in the 8 months preceding, and following the
introduction of Mydriasert. The statistical significance
of any change in iris hook orders (as a proportion of
cataract operations performed) was determined using
the chi-squared test.
Results
Impact of mydriasert in clinical practice
Ninety-seven nursing proformas were returned (mean
patient age = 74.9 years [range 49 years to 91 years];
45 % were female and 55 % male) and 114 surgical
proformas were completed (mean patient age = 72.6 years
[range 48 years to 91 years]; 41 % were male, and
59 % female) for the clinical evaluation of Mydriasert
in cataract surgery.
The average nursing time spent inserting Mydriasert
was 1.52 ± 0.60 minutes (mean ± SD, n = 85) which wasused as an input for the economic model (Table 1).
Using Mydriasert to induce dilation, pupil size (defined
by the pupil size score from 1 to 4) was generally large
or very large (mean score ± SD, 3.32 ± 0.66; n = 114)
(Fig. 2a) which was sustained for up to 300 minutes after
pellet insertion (Fig. 2b). Patients were very satisfied with
the procedure based on a satisfaction score from 1 to 10
(mean score ± SD, 8.97 ± 1.32; n = 97).
The insert was not found in three cases. In one case
the anaesthetist forgot to the remove the insert, although
it was subsequently discovered and removed at speculum
placement. An area of epithelial irregularity was noted
under the operating microscope at the start of one case
and this had not been present when the patient had been
examined at the slit lamp earlier that day. The patient was
treated with a course of chloramphenicol ointment and
Fig. 3 Annual total healthcare costs in the base case. Base case total
healthcare cost analysis for Mydriasert compared to eye drops
(tropicamide [1 %] and phenylephrine [10 %]) to induce mydriasis
for a cohort of 1763 patients at a Greater London district general
hospital undergoing cataract surgery from 2012-2013
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re-examined 1 week later.
If the surgeon was concerned that the pupil was exces-
sively dilated at the end of surgery, the pupil could be con-
stricted by injecting Miochol (Bausch & Lomb) into the
anterior chamber. Pharmacy data was requested for a
12 month period before, and after, the introduction of
Mydriasert. Prior to Mydriasert 191 doses of Miochol
were ordered (1547 cataract operations performed) versus
200 doses following Mydriasert (1659 cataract operations
performed). There was no significant difference in the rate
of Miochol use before versus after the introduction of
Mydriasert (p = 0.83, Fishers exact test) and hence the cost
of Miochol was not considered in the economic model.
Cost analysis of mydriasert compared with mydriatic eye
drops
The base case analysis showed that when Mydriasert
substituted mydriatic eye drops, annual total costs decreased
by 18 %, saving £2111 (£1.20 per patient) (Table 2; Fig. 3).
Annual total nurse time decreased from 235.1 hours
to 44.1 hours when Mydriasert replaced mydriatic eye
drops, which represented a total reduction in nursing
costs from £9873 to £1851 (Table 2; Fig. 3). Sensitivity
analysis confirmed that nurse time to instil mydriatic eye
drops was a key cost driver in the economic model (data
not shown).
A statistically significant reduction in iris hooks ordered
was observed after the introduction of Mydriasert for cata-
ract surgery. In the 8 months prior to Mydriasert use, 32
iris hooks were ordered (2.78 %, 1155 cataract surgeries
performed) compared to 12 iris hooks (1.0 %, 1198 cataract
surgeries performed) in the subsequent 8 months following
introduction of Mydriasert (p = 0.03, chi-squared test).
Scenario analysis incorporating the incidence of use,
surgeon time (10 minutes) and the cost of iris hooks
(£54 per case) into the economic model estimated a total
annual cost saving of £4559 (£2.59 per patient) using
Mydriasert compared with mydriatic eye drops.Table 2 Base case analysis for Mydriasert compared to eye
drops (tropicamide [1 %] and phenylephrine [10 %]) to induce
mydriasis for a patient cohort* undergoing cataract surgery
from 2012-2013
Mydriasert Eye drops Difference
Mydriasert costs (£) 7598 0 7598
Eye-drops costs (£) 0 1687 -1687
Nurse costs (£) 1851 9873 - 8022
Annual total costs (£) 9449 11 560 -2111
Costs per patient (£) 5.36 6.56 -1.20
Annual total nurse time (hours) 44.1 235.1 -191.0
*N = 1763 cataract surgery patients and a single London hospital in one year.
2013 drug costs 2013 and 2012 nurse/consultant costs were usedDiscussion
A budget impact model was developed to estimate the
drug, consumable and staff costs for achieving mydriasis
using Mydriasert compared with mydriatic eye drops.
The model was designed to assist NHS managers and
local payers when considering the budget impact of
introducing Mydriasert to their hospital settings. Interviews
with clinicians and a clinical evaluation of cataract surgeries
using Mydriasert at a district general hospital in Greater
London provided input parameters for the model.
Using the designated hospital population of 1763 cataract
surgery patients for the base case analysis, this study
demonstrated that compared with traditional mydriatic eye
drops, Mydriasert provided comparable clinical outcomes
with overall savings in health-care costs mainly associated
with reduced nurse time. This study also supports
previous investigations which demonstrated the effi-
cacy of Mydriasert to produce stable pupillary dilation
[1–8]. After a single application of Mydriasert, sustained
pupil dilation was achieved. The dilation achieved was suit-
able for the duration of cataract surgery enabling nursing
staff to insert Mydriasert pellets for a group of patients
simultaneously. This removed the need for repeated
patient visits to increase efficiency, minimise other work-
load interruption, and provided the assurance that the
pupil would stay dilated even if surgery was delayed. In
contrast, the previous protocol used for pre-operative pupil
dilatation at the district general hospital where the
study was conducted required at least four instillations of
mydriatic eye drops.
In practise, some ophthalmology units may use a less
rigid dilation regime with regular monitoring, topping
up mydriatic eye drops as necessary to ensure sufficient
dilation is achieved prior to cataract surgery. However, if
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manner the size of the pupil may be reduced and this is
a recognised risk factor for the complication of posterior
capsule rupture [13]. With the increasing age of the
general population, the demand for cataract surgery is
expected to increase in the future [14], thus cost-saving
methods that improve the efficiency of healthcare practi-
tioners should be considered.
In the scenario analysis, the number of iris hooks ordered
reduced by 63 % since the introduction of Mydriasert.
This suggested that Mydriasert may reduce the frequency
of iris hooks required during cataract surgery, subse-
quently reducing expenditure on hooks and the associated
costs incurred by involving the surgeon’s time. Further
studies are required that actively exclude or control
confounding variables around the measurement of iris
hook usage.
Although the Mydriasert pellet is more expensive
than mydriatic eye drops, the higher cost was offset
by increased nurse time required for instillation of
the eye drops. A limitation of the model was that a
one-off cost of nurse training (which may be variable)
was not included which could impact the cost savings
achieved, however the model was designed to compare a
steady state use of Mydriasert and mydriatic eye drops in
clinical practice. Data collected during the first month of
use report that the average time required for nurses to
insert Mydriasert was 1.5 minutes; this time is likely to
decrease as nurses gain more experience with Mydriasert.
Since sensitivity analysis showed the nurse time was a key
cost driver in the economic model (data not shown), the
costs associated with Mydriasert could decrease further
over time.Conclusions
An economic analysis of a cohort of patients undergoing
cataract surgery at a Greater London district general hos-
pital showed that despite its higher unit cost, Mydriasert
was cost saving overall compared with mydriatic eye drops.
The reduction in costs was attributed to the decrease in
nursing time required for Mydriasert compared with
mydriatic eye drops thus; Mydriasert improved efficiency
and could enable nurses to spend more time on other
activities.
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